Login Register Cart 0
Review Article

基于MicroRNA的肺癌生物标志物：最新进展和潜在应用

卷 23, 期 7, 2023

发表于: 13 September, 2022

页: [648 - 667] 页: 20

弟呕挨: 10.2174/2772432817666220520085719

价格: $65

conference banner
摘要

简介： MicroRNA（miRNA）是一组小的非编码RNA（ncRNA），通过结合和降解其靶mRNA来控制基因的表达。miRNA可以作为各种癌症中可能的肿瘤抑制因子或癌基因。最近，miRNA作为不同疾病的生物标志物（预后和诊断）的应用引起了广泛关注。miRNA以稳定的形式存在于几种生物材料中，包括组织、血浆和血清。在血清、血液、组织和其他体液中对miRNA进行无创且易于筛选以及可接受的稳定性使microRNA成为人类恶性肿瘤中生物标志物的明显因素。 材料和方法：在本综述中，我们检索了一些在线数据库，如Web of Science，Embase和PubMed，以找到截至2021年底的合格稿件。 结果：这些分子的异常表达与许多疾病的发病率有关，如癌症。因此，它们是非侵入性肿瘤预后和诊断的分子工具的候选者。在目前的研究中，我们引入了重要的miRNA，可用作肺癌患者的预后和诊断标志物。 结论：我们总结了与肺部患者诊断和预后相关的关键miRNA的最新报道

关键词: 肺癌，miRNA，生物标志物，诊断，预后，NSCLC

« Previous Next »
[1]
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144(8): 1941-53.
[2]
Zarredar H, Ansarin K, Baradaran B, Ahdi Khosroshahi S, Farajnia S. Potential molecular targets in the treatment of lung cancer using siRNA technology. Cancer Invest 2018; 36(1): 37-58.
[http://dx.doi.org/10.1080/07357907.2017.1416393] [PMID: 29336624]
[3]
Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: A national cancer database survey. J Thorac Oncol 2010; 5(1): 29-33.
[4]
Zarredar H, Ansarin K, Baradaran B, et al. Critical microRNAs in lung cancer: recent advances and potential applications. Anticancer Agents Med Chem 2018; 18(14): 1991-2005.
[http://dx.doi.org/10.2174/1871520618666180808125459] [PMID: 30088452]
[5]
Chen J, Lou J, Yang S, et al. MT1JP inhibits glioma progression via negative regulation of miR-24. Oncol Lett 2020; 19(1): 334-42.
[PMID: 31890049]
[6]
Wu K-L, Tsai Y-M, Lien C-T, Kuo P-L, Hung AJ. The roles of MicroRNA in lung cancer. Int J Mol Sci 2019; 20(7): 1611.
[http://dx.doi.org/10.3390/ijms20071611] [PMID: 30935143]
[7]
Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11): 3753-6.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-0637] [PMID: 15172979]
[8]
Manodoro F, Marzec J, Chaplin T, et al. Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood 2014; 123(13): 2066-74.
[http://dx.doi.org/10.1182/blood-2012-12-469833] [PMID: 24493669]
[9]
Safary A, Moniri R, Hamzeh-Mivehroud M, Dastmalchi S. Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant Bacillus strain. Bioimpacts 2019; 9(1): 15-23.
[http://dx.doi.org/10.15171/bi.2019.03] [PMID: 30788256]
[10]
Nazarizadeh A, Mohammadi F, Alian F, Faraji P, Nourbakhsh M, Alizadeh-Fanalou S. MicroRNA-154: A novel candidate for diagnosis and therapy of human cancers. OncoTargets Ther 2020; 13: 6603-15.
[http://dx.doi.org/10.2147/OTT.S249268] [PMID: 32753896]
[11]
Lin X, Yang Z, Zhang P, Shao G. miR-154 suppresses non-small cell lung cancer growth in vitro and in vivo. Oncol Rep 2015; 33(6): 3053-60.
[http://dx.doi.org/10.3892/or.2015.3895] [PMID: 25846246]
[12]
Lin X, Yang Z, Zhang P, Liu Y, Shao G. miR-154 inhibits migration and invasion of human non-small cell lung cancer by targeting ZEB2. Oncol Lett 2016; 12(1): 301-6.
[http://dx.doi.org/10.3892/ol.2016.4577] [PMID: 27347142]
[13]
Liu S, Yang Y, Chen L, Liu D, Dong H. MicroRNA-154 functions as a tumor suppressor in non-small cell lung cancer through directly targeting B-cell-specific Moloney murine leukemia virus insertion site 1. Oncol Lett 2018; 15(6): 10098-104.
[http://dx.doi.org/10.3892/ol.2018.8595] [PMID: 29928380]
[14]
Xue Y-J, Fu Y-J, Wang J-H. The inhibitory effect of miR-154-3p on metastasis of non-small cell lung cancer cell lines. TUMOR 2015; 35(5): 498-507.
[15]
Kai Y, Qiang C, Xinxin P, Miaomiao Z, Kuailu L. Decreased miR-154 expression and its clinical significance in human colorectal cancer. World J Surg Oncol 2015; 13(1): 195.
[http://dx.doi.org/10.1186/s12957-015-0607-5] [PMID: 26048406]
[16]
Lingling J, Xiangao J, Guiqing H, Jichan S, Feifei S, Haiyan Z. SNHG20 knockdown suppresses proliferation, migration and invasion, and promotes apoptosis in non-small cell lung cancer through acting as a miR-154 sponge. Biomed Pharmacother 2019; 112: 108648.
[http://dx.doi.org/10.1016/j.biopha.2019.108648] [PMID: 30780105]
[17]
Hong S, Bi M, Chen S, et al. MicroRNA-520f suppresses growth of gastric carcinoma cells by target ATPase family AAA domain-containing protein 2 (ATAD2). Neoplasma 2016; 63(6): 873-9.
[http://dx.doi.org/10.4149/neo_2016_606] [PMID: 27565325]
[18]
Zhou Y, Shen S. MiR-520f acts as a biomarker for the diagnosis of lung cancer. Medicine 2019; 98(30): e16546.
[http://dx.doi.org/10.1097/MD.0000000000016546] [PMID: 31348274]
[19]
Cui J, Li W, Liu G, et al. A novel circular RNA, hsa_circ_0043278, acts as a potential biomarker and promotes non-small cell lung cancer cell proliferation and migration by regulating miR-520f. Artif Cells Nanomed Biotechnol 2019; 47(1): 810-21.
[http://dx.doi.org/10.1080/21691401.2019.1575847] [PMID: 30873868]
[20]
van Kampen JGM, van Hooij O, Jansen CF, et al. miRNA-520f reverses epithelial-to-mesenchymal transition by targeting ADAM9 and TGFBR2. Cancer Res 2017; 77(8): 2008-17.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-2609] [PMID: 28209612]
[21]
Meister J, Schmidt MHH. miR-126 and miR-126*: New players in cancer. ScientificWorldJournal 2010; 10: 2090-100.
[http://dx.doi.org/10.1100/tsw.2010.198] [PMID: 20953557]
[22]
Tao SC, Guo SC, Li M, Ke QF, Guo YP, Zhang CQ. Chitosan wound dressings incorporating exosomes derived from MicroRNA-126 overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model. Stem Cells Transl Med 2017; 6(3): 736-47.
[http://dx.doi.org/10.5966/sctm.2016-0275] [PMID: 28297576]
[23]
Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451(7175): 147-52.
[http://dx.doi.org/10.1038/nature06487] [PMID: 18185580]
[24]
Tomasetti M, Staffolani S, Nocchi L, et al. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 2012; 45(7-8): 575-81.
[http://dx.doi.org/10.1016/j.clinbiochem.2012.02.009] [PMID: 22374169]
[25]
Ebrahimi F, Gopalan V, Smith RA, Lam AK. miR-126 in human cancers: Clinical roles and current perspectives. Exp Mol Pathol 2014; 96(1): 98-107.
[http://dx.doi.org/10.1016/j.yexmp.2013.12.004] [PMID: 24368110]
[26]
Hamada S, Satoh K, Fujibuchi W, et al. MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. MCR 2012; 10(1): 3-10.
[http://dx.doi.org/10.1158/1541-7786.MCR-11-0272] [PMID: 22064652]
[27]
Lin Q, Mao W, Shu Y, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J Cancer Res Clin Oncol 2012; 138(1): 85-93.
[http://dx.doi.org/10.1007/s00432-011-1068-z] [PMID: 22009180]
[28]
Cao WJ, Rosenblat JD, Roth NC, et al. Therapeutic angiogenesis by ultrasound-mediated microRNA-126-3p delivery. Arterioscler Thromb Vasc Biol 2015; 35(11): 2401-11.
[http://dx.doi.org/10.1161/ATVBAHA.115.306506] [PMID: 26381870]
[29]
Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 2010; 391(3): 1483-9.
[http://dx.doi.org/10.1016/j.bbrc.2009.12.098] [PMID: 20034472]
[30]
Huang TH, Chu TY. Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer. Oncogene 2014; 33(28): 3636-47.
[http://dx.doi.org/10.1038/onc.2013.335] [PMID: 24037526]
[31]
Rodríguez M, Silva J, López-Alfonso A, et al. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer. Genes Chromosomes Cancer 2014; 53(9): 713-24.
[http://dx.doi.org/10.1002/gcc.22181] [PMID: 24764226]
[32]
Song L, Li D, Gu Y, et al. MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer 2016; 17(5): e65-75.
[http://dx.doi.org/10.1016/j.cllc.2016.03.012] [PMID: 27236384]
[33]
Shang AQ, Xie YN, Wang J, et al. Predicative values of serum microRNA-22 and microRNA-126 levels for non-small cell lung cancer development and metastasis: A case-control study. Neoplasma 2017; 64(3): 453-9.
[http://dx.doi.org/10.4149/neo_2017_317] [PMID: 28253725]
[34]
Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS One 2016; 11(4): e0153046.
[http://dx.doi.org/10.1371/journal.pone.0153046] [PMID: 27093275]
[35]
Kim M-H, Jo EJ, Eom JS, et al. Diagnostic value of microRNAs derived exosomes from bronchoalveolar lavage fluid in early stage lung adenocarcinoma. Chest 2016; 150(4): 703A.
[http://dx.doi.org/10.1016/j.chest.2016.08.798]
[36]
Jusufović E, Rijavec M, Keser D, et al. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer. PLoS One 2012; 7(9): e45577.
[http://dx.doi.org/10.1371/journal.pone.0045577] [PMID: 23029111]
[37]
Yang J, Lan H, Huang X, Liu B, Tong Y. MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One 2012; 7(8): e42978.
[http://dx.doi.org/10.1371/journal.pone.0042978] [PMID: 22900072]
[38]
Zhu X, Li H, Long L, et al. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin 2012; 44(6): 519-26.
[http://dx.doi.org/10.1093/abbs/gms026] [PMID: 22510476]
[39]
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133(2): 647-58.
[http://dx.doi.org/10.1053/j.gastro.2007.05.022] [PMID: 17681183]
[40]
Bovell LC, Shanmugam C, Putcha BD, et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 2013; 19(14): 3955-65.
[http://dx.doi.org/10.1158/1078-0432.CCR-12-3302] [PMID: 23719259]
[41]
Guo Q, Zhang H, Zhang L, et al. MicroRNA-21 regulates non-small cell lung cancer cell proliferation by affecting cell apoptosis via COX-19. Int J Clin Exp Med 2015; 8(6): 8835-41.
[PMID: 26309536]
[42]
Xiong B, Cheng Y, Ma L, Zhang C. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 2013; 42(1): 219-28.
[http://dx.doi.org/10.3892/ijo.2012.1707] [PMID: 23174819]
[43]
Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18(3): 282-93.
[http://dx.doi.org/10.1016/j.ccr.2010.08.013] [PMID: 20832755]
[44]
Chen Z, Liu H, Jin W, Ding Z, Zheng S, Yu Y. Tissue microRNA-21 expression predicted recurrence and poor survival in patients with colorectal cancer - a meta-analysis. OncoTargets Ther 2016; 9: 2615-24.
[PMID: 27226723]
[45]
Cinegaglia NC, Andrade SC, Tokar T, et al. Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma. Oncotarget 2016; 7(20): 28920-34.
[http://dx.doi.org/10.18632/oncotarget.8713] [PMID: 27081085]
[46]
Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15(1): 4-9.
[PMID: 19262443]
[47]
Zhu W, Xu B. MicroRNA-21 identified as predictor of cancer outcome: A meta-analysis. PLoS One 2014; 9(8): e103373.
[http://dx.doi.org/10.1371/journal.pone.0103373] [PMID: 25098165]
[48]
Tian L, Shan W, Zhang Y, Lv X, Li X, Wei C. Up-Regulation of miR-21 expression predicate advanced clinicopathological features and poor prognosis in patients with non-small cell lung cancer. Pathol Oncol Res 2016; 22(1): 161-7.
[http://dx.doi.org/10.1007/s12253-015-9979-7] [PMID: 26453197]
[49]
Liu XG, Zhu WY, Huang YY, et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012; 29(2): 618-26.
[http://dx.doi.org/10.1007/s12032-011-9923-y] [PMID: 21516486]
[50]
Sun X, Liu B, Zhao XD, Wang LY, Ji WY. MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1. Oncol Rep 2015; 33(3): 1221-6.
[http://dx.doi.org/10.3892/or.2015.3714] [PMID: 25586265]
[51]
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010; 411(11-12): 846-52.
[http://dx.doi.org/10.1016/j.cca.2010.02.074] [PMID: 20223231]
[52]
Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. MiRNA-21: A biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 2012; 13(5): 330-40.
[http://dx.doi.org/10.4161/cbt.19073] [PMID: 22237007]
[53]
Stenvold H, Donnem T, Andersen S, et al. High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome. BMC Clin Pathol 2014; 14(1): 9.
[http://dx.doi.org/10.1186/1472-6890-14-9] [PMID: 24524655]
[54]
de Souza Rocha Simonini P, Breiling A, Gupta N, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70(22): 9175-84.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-1318] [PMID: 20978187]
[55]
Jonsdottir K, Janssen SR, Da Rosa FC, et al. Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One 2012; 7(11): e48692-2.
[http://dx.doi.org/10.1371/journal.pone.0048692] [PMID: 23144930]
[56]
Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, et al. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 2013; 24(11): 1638-48.
[http://dx.doi.org/10.1091/mbc.e12-12-0891]
[57]
Yeh C-B, Hsieh M-J, Hsieh Y-S, et al. Terminalia catappa exerts antimetastatic effects on hepatocellular carcinoma through transcriptional inhibition of matrix metalloproteinase-9 by modulating NF-κB and AP-1 activity. Evid Based Complement Alternat Med 2012; 2012: 595292.
[http://dx.doi.org/10.1155/2012/595292] [PMID: 23258989]
[58]
Jin Y, Liu Y, Zhang J, et al. The expression of miR-375 is associated with carcinogenesis in three subtypes of lung cancer. PLoS One 2015; 10(12): e0144187.
[http://dx.doi.org/10.1371/journal.pone.0144187] [PMID: 26642205]
[59]
Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. Gene 2014; 534(1): 60-5.
[http://dx.doi.org/10.1016/j.gene.2013.10.024] [PMID: 24404590]
[60]
Li Y, Jiang Q, Xia N, Yang H, Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res 2012; 40(5): 1662-9.
[http://dx.doi.org/10.1177/030006051204000505] [PMID: 23206448]
[61]
Lu S, Kong H, Hou Y, et al. Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer. Lung Cancer 2018; 123: 44-51.
[http://dx.doi.org/10.1016/j.lungcan.2018.06.027] [PMID: 30089594]
[62]
Cheng L, Zhan B, Luo P, Wang B. miRNA-375 regulates the cell survival and apoptosis of human non-small cell carcinoma by targeting HER2. Mol Med Rep 2017; 15(3): 1387-92.
[http://dx.doi.org/10.3892/mmr.2017.6112] [PMID: 28098887]
[63]
Mao S, Zheng S, Lu Z, et al. Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. Transl Lung Cancer Res 2021; 10(7): 3155-72.
[http://dx.doi.org/10.21037/tlcr-21-356] [PMID: 34430355]
[64]
Nadal E, Zhong J, Lin J, et al. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res 2014; 20(12): 3107-17.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-3348] [PMID: 24833665]
[65]
Zhao Z, Qin L, Li S. miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1. Tumour Biol 2016; 37(4): 5551-60.
[http://dx.doi.org/10.1007/s13277-015-4425-8] [PMID: 26572153]
[66]
Zhang C, Wang H, Liu X, et al. Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP. Oncogene 2019; 38(11): 1892-904.
[http://dx.doi.org/10.1038/s41388-018-0534-3] [PMID: 30390072]
[67]
Wang SY, Li Y, Jiang YS, Li RZ. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2017; 21(18): 4092-7.
[PMID: 29028091]
[68]
Zhao W-X, Tang Y-L, Wang W-H, Bao M-W. Up-regulation of circ_0000353 impedes the proliferation and metastasis of non-small cell lung cancer cells via adsorbing miR-411-5p and increasing forkhead box O1. Cancer Biomark 2020; 29(1): 25-37.
[69]
Pal D, Ghatak S, Sen CK. Epigenetic modification of microRNAs: MicroRNA in Regenerative Medicine. Elsevier 2015; pp. 77-109.
[http://dx.doi.org/10.1016/B978-0-12-405544-5.00003-4]
[70]
Zheng L, Qi T, Yang D, et al. microRNA-9 suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting cyclin D1 and Ets1. PLoS One 2013; 8(1): e55719.
[http://dx.doi.org/10.1371/journal.pone.0055719] [PMID: 23383271]
[71]
Xu T, Liu X, Han L, Shen H, Liu L, Shu Y. Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol 2014; 16(5): 469-75.
[http://dx.doi.org/10.1007/s12094-013-1106-1] [PMID: 24019037]
[72]
Zhou X, Marian C, Makambi KH, et al. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status. PLoS One 2012; 7(6): e39011.
[http://dx.doi.org/10.1371/journal.pone.0039011] [PMID: 22723919]
[73]
Han L, Wang W, Ding W, Zhang L. MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7. J Cell Mol Med 2017; 21(9): 2000-8.
[http://dx.doi.org/10.1111/jcmm.13120] [PMID: 28266181]
[74]
Wang H, Wu Q, Zhang Y, Zhang H-N, Wang Y-B, Wang W. TGF-β1-induced epithelial-mesenchymal transition in lung cancer cells involves upregulation of miR-9 and downregulation of its target, E-cadherin. Cell Mol Biol Lett 2017; 22(1): 22-2.
[http://dx.doi.org/10.1186/s11658-017-0053-1] [PMID: 29118814]
[75]
Li G, Wu F, Yang H, Deng X, Yuan Y. MiR-9-5p promotes cell growth and metastasis in non-small cell lung cancer through the repression of TGFBR2. Biomed Pharmacother 2017; 96: 1170-8.
[http://dx.doi.org/10.1016/j.biopha.2017.11.105] [PMID: 29239816]
[76]
Muraoka T, Soh J, Toyooka S, et al. Impact of aberrant methylation of microRNA-9 family members on non-small cell lung cancers. Mol Clin Oncol 2013; 1(1): 185-9.
[http://dx.doi.org/10.3892/mco.2012.18] [PMID: 24649145]
[77]
Bediaga NG, Davies MP, Acha-Sagredo A, et al. A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. Br J Cancer 2013; 109(9): 2404-11.
[http://dx.doi.org/10.1038/bjc.2013.623] [PMID: 24113142]
[78]
Chen X, Zhu L, Ma Z, et al. Oncogenic miR-9 is a target of erlotinib in NSCLCs. Sci Rep 2015; 5(1): 17031.
[http://dx.doi.org/10.1038/srep17031] [PMID: 26593208]
[79]
Wang K, Xu K, Leng X, Han Y, Fang Q. miRNA-9 inhibits proliferation and migration of lung squamous cell carcinoma cells by regulating NRSF/EGFR. Technol Cancer Res Treat 2020; 19: 1533033820945807.
[http://dx.doi.org/10.1177/1533033820945807] [PMID: 32772818]
[80]
Rizos E, Siafakas N, Katsantoni E, et al. Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia. PLoS One 2015; 10(4): e0123522.
[http://dx.doi.org/10.1371/journal.pone.0123522] [PMID: 25856466]
[81]
Roberts SA, Kaiser UB. GENETICS IN ENDOCRINOLOGY: Genetic etiologies of central precocious puberty and the role of imprinted genes. Eur J Endocrinol 2020; 183(4): R107-17.
[http://dx.doi.org/10.1530/EJE-20-0103] [PMID: 32698138]
[82]
Wang K, Dong L, Fang Q, Xia H, Hou X. Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer. Cancer Biomark 2017; 20(3): 283-8.
[http://dx.doi.org/10.3233/CBM-170124] [PMID: 28946561]
[83]
Ni R, Huang Y, Wang J. miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer. OncoTargets Ther 2015; 8: 2689-97.
[PMID: 26445551]
[84]
Yang G, Zhang X, Shi J. MiR-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting PAK1. Int J Clin Exp Med 2015; 8(11): 20135-45.
[PMID: 26884926]
[85]
Du L, Schageman JJ, Subauste MC, et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009; 7(8): 1234-43.
[http://dx.doi.org/10.1158/1541-7786.MCR-08-0507] [PMID: 19671678]
[86]
Jiang F, Yu Q, Chu Y, et al. MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol 2019; 54(1): 128-38.
[PMID: 30387848]
[87]
Deng Z-Q, Yin J-Y, Tang Q, et al. Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients. Int J Clin Exp Pathol 2014; 7(3): 1166-71.
[PMID: 24696733]
[88]
Wu F, Mo Q, Wan X, Dan J, Hu H. NEAT1/hsa-mir-98-5p/MAPK6 axis is involved in non-small-cell lung cancer development. J Cell Biochem 2019; 120(3): 2836-46.
[http://dx.doi.org/10.1002/jcb.26442] [PMID: 29095526]
[89]
Zhou H, Huang Z, Chen X, Chen S. miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. Biomed Pharmacother 2017; 89: 1453-61.
[http://dx.doi.org/10.1016/j.biopha.2017.01.012] [PMID: 28415380]
[90]
Liu W, Xiao P, Wu H, Wang L, Kong D, Micro YuF. RNA-98 plays a suppressive role in non-small cell lung cancer through inhibition of SALL4 protein expression. Oncol Res 2017; 25(6): 975-88.
[http://dx.doi.org/10.3727/096504016X14791726591124]
[91]
Tang Y, Wu L, Zhao M, et al. LncRNA SNHG4 promotes the proliferation, migration, invasiveness, and epithelial-mesenchymal transition of lung cancer cells by regulating miR-98-5p. Biochem Cell Biol 2019; 97(6): 767-76.
[http://dx.doi.org/10.1139/bcb-2019-0065] [PMID: 31220419]
[92]
ElKhouly AM, Youness RA, Gad MZ. MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions. Noncoding RNA Res 2020; 5(1): 11-21.
[http://dx.doi.org/10.1016/j.ncrna.2020.01.001] [PMID: 31993547]
[93]
Wang J, Tian X, Han R, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 2014; 33(9): 1181-9.
[http://dx.doi.org/10.1038/onc.2013.42] [PMID: 23474761]
[94]
Tian F, Wang J, Ouyang T, et al. MiR-486-5p serves as a good biomarker in nonsmall cell lung cancer and suppresses cell growth with the involvement of a target PIK3R1. Front Genet 2019; 10: 688-8.
[http://dx.doi.org/10.3389/fgene.2019.00688] [PMID: 31402930]
[95]
Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010; 28(10): 1721-6.
[http://dx.doi.org/10.1200/JCO.2009.24.9342] [PMID: 20194856]
[96]
Pang W, Tian X, Bai F, et al. Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer. Mol Cancer 2014; 13(1): 240.
[http://dx.doi.org/10.1186/1476-4598-13-240] [PMID: 25342548]
[97]
Tian F, Shen Y, Chen Z, Li R, Lu J, Ge Q. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene 2016; 591(2): 338-43.
[http://dx.doi.org/10.1016/j.gene.2016.06.014] [PMID: 27291819]
[98]
Chen T, Zhu J, Cai T, et al. Suppression of non-small cell lung cancer migration and invasion by hsa-miR-486-5p via the TGF-β/SMAD2 signaling pathway. J Cancer 2019; 10(24): 6014-24.
[http://dx.doi.org/10.7150/jca.35017] [PMID: 31762811]
[99]
Jin B, Jin H, Wu HB, Xu JJ, Li B. Long non-coding RNA SNHG15 promotes CDK14 expression via miR-486 to accelerate non-small cell lung cancer cells progression and metastasis. J Cell Physiol 2018; 233(9): 7164-72.
[http://dx.doi.org/10.1002/jcp.26543] [PMID: 29630731]
[100]
Wang A, Zhu J, Li J, et al. Downregulation of KIAA1199 by miR-486-5p suppresses tumorigenesis in lung cancer. Cancer Med 2020; 9(15): 5570-86.
[http://dx.doi.org/10.1002/cam4.3210] [PMID: 32519472]
[101]
Tian F, Ouyang T, Lu N, Shen Y, Bai Y, Xie X, et al. MiR-486-5p serves as a good biomarker in NSCLC and suppresses cell growth with the involvement of a target-PIK3R1. Front Genet 2019; 10: 688.
[http://dx.doi.org/10.3389/fgene.2019.00688] [PMID: 31402930]
[102]
Xing Z, Zhang Z, Gao Y, et al. The lncRNA LINC01194/miR-486-5p axis facilitates malignancy in non-small cell lung cancer via regulating CDK4. OncoTargets Ther 2020; 13: 3151-63.
[http://dx.doi.org/10.2147/OTT.S235037] [PMID: 32346298]
[103]
Yu S, Geng S, Hu Y. miR-486-5p inhibits cell proliferation and invasion through repressing GAB2 in non-small cell lung cancer. Oncol Lett 2018; 16(3): 3525-30.
[http://dx.doi.org/10.3892/ol.2018.9053] [PMID: 30127957]
[104]
Li W, Wang Y, Zhang Q, et al. MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One 2015; 10(8): e0134220.
[http://dx.doi.org/10.1371/journal.pone.0134220] [PMID: 26237047]
[105]
Ouzounova M, Vuong T, Ancey P-B, et al. MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics 2013; 14(1): 139.
[http://dx.doi.org/10.1186/1471-2164-14-139] [PMID: 23445407]
[106]
Jiang L-H, Zhang H-D, Tang J-H. MiR-30a: A novel biomarker and potential therapeutic target for cancer. Journal of Oncology 2018; 2018
[http://dx.doi.org/10.1155/2018/5167829]
[107]
Zhong Z, Xia Y, Wang P, Liu B, Chen Y. Low expression of microRNA-30c promotes invasion by inducing epithelial mesenchymal transition in non-small cell lung cancer. Mol Med Rep 2014; 10(5): 2575-9.
[http://dx.doi.org/10.3892/mmr.2014.2494] [PMID: 25119247]
[108]
Zhong K, Chen K, Han L, Li B. MicroRNA-30b/c inhibits non-small cell lung cancer cell proliferation by targeting Rab18. BMC Cancer 2014; 14(1): 703.
[http://dx.doi.org/10.1186/1471-2407-14-703] [PMID: 25249344]
[109]
Wen XP, Ma HL, Zhao LY, Zhang W, Dang CX. MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R. Cell Mol Biol 2015; 61(2): 78-85.
[PMID: 26025408]
[110]
Luan N, Wang Y, Liu X. Absent expression of miR-30a promotes the growth of lung cancer cells by targeting MEF2D. Oncol Lett 2018; 16(1): 1173-9.
[http://dx.doi.org/10.3892/ol.2018.8719] [PMID: 29963192]
[111]
Xu X, Jin S, Ma Y, et al. miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. J Mol Med 2017; 95(8): 861-71.
[http://dx.doi.org/10.1007/s00109-017-1539-z] [PMID: 28487996]
[112]
Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012; 130(9): 2044-53.
[http://dx.doi.org/10.1002/ijc.26218] [PMID: 21633953]
[113]
Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219(2): 214-21.
[http://dx.doi.org/10.1002/path.2586] [PMID: 19593777]
[114]
Świtlik W, Karbownik MS, Suwalski M, Kozak J, Szemraj J. miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: A preliminary study. Dis Markers 2018; 21(2): 479-88.
[http://dx.doi.org/10.3233/CBM-170767] [PMID: 29103030]
[115]
Zhu J, Zeng Y, Li W, et al. CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Mol Cancer 2017; 16(1): 34-4.
[http://dx.doi.org/10.1186/s12943-017-0591-1] [PMID: 28158983]
[116]
Sun L, Chen Y, Su Q, et al. Increased plasma miRNA-30a as a biomarker for non-small cell lung cancer. Med Sci Monit 2016; 22: 647-55.
[http://dx.doi.org/10.12659/MSM.897330] [PMID: 26918265]
[117]
Wang F, Meng F, Wong SCC, Cho WCS, Yang S, Chan LWC. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer. Ther Adv Respir Dis 2020; 14: 1753466620915156.
[http://dx.doi.org/10.1177/1753466620915156] [PMID: 32552611]
[118]
Zarredar H, Farajnia S, Ansarin K, Baradaran B, Aria M, Asadi M. Synergistic effect of novel EGFR inhibitor AZD8931 and p38α siRNA in lung adenocarcinoma cancer cells. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2019; 19(5): 638-44.
[119]
Li J, Xu X, Wei C, Liu L, Wang T. Long noncoding RNA NORAD regulates lung cancer cell proliferation, apoptosis, migration, and invasion by the miR-30a-5p/ADAM19 axis. Int J Clin Exp Pathol 2020; 13(1): 1-13.
[PMID: 32055266]
[120]
Tang R, Liang L, Luo D, et al. Downregulation of MiR-30a is associated with poor prognosis in lung cancer. Med Sci Monit 2015; 21: 2514-20.
[http://dx.doi.org/10.12659/MSM.894372] [PMID: 26305739]
[121]
Wu W, Zhao Y, Gao E, et al. LncRNA DLEU2 accelerates the tumorigenesis and invasion of non-small cell lung cancer by sponging miR-30a-5p. J Cell Mol Med 2020; 24(1): 441-50.
[http://dx.doi.org/10.1111/jcmm.14749] [PMID: 31721438]
[122]
Li X, Liu J, Liu M, Xia C, Zhao Q. The Lnc LINC00461/miR-30a-5p facilitates progression and malignancy in non-small cell lung cancer via regulating ZEB2. Cell Cycle 2020; 19(7): 825-36.
[http://dx.doi.org/10.1080/15384101.2020.1731946] [PMID: 32106756]
[123]
Ma YS, Yu F, Zhong XM, Lu GX. miR-30 family reduction maintains self-renewal and promotes tumorigenesis in NSCLC-Initiating cells by targeting oncogene TM4SF1. Mol Ther 2018; 26(12): 2751-65.
[124]
Yan J, Ma C, Gao Y. MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. Oncol Rep 2017; 37(5): 3146-54.
[http://dx.doi.org/10.3892/or.2017.5566] [PMID: 28405690]
[125]
Jiang X, Yuan Y, Tang L, et al. Identification and validation prognostic impact of MiRNA-30a-5p in lung adenocarcinoma. Front Oncol 2022; 12: 470.
[126]
Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009; 27(12): 2030-7.
[http://dx.doi.org/10.1200/JCO.2008.19.4134] [PMID: 19273703]
[127]
Adachi R, Horiuchi S, Sakurazawa Y, Hasegawa T, Sato K, Sakamaki T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem Biophys Res Commun 2011; 411(4): 804-8.
[http://dx.doi.org/10.1016/j.bbrc.2011.07.033] [PMID: 21787752]
[128]
Cai J, Fang L, Huang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res 2013; 73(17): 5402-15.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-0297] [PMID: 23856247]
[129]
Duan B, Guo T, Sun H, Cai R, Rui Q, Xi Z. miR-205 as a biological marker in non-small cell lung cancer. Biomed Pharmacother 2017; 91: 823-30.
[http://dx.doi.org/10.1016/j.biopha.2017.04.086] [PMID: 28501009]
[130]
Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010; 16(2): 610-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-2638] [PMID: 20068099]
[131]
Li J-H, Sun S-S, Li N, Lv P, Xie S-Y, Wang P-Y. MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer. Oncotarget 2017; 8(54): 91938-49.
[http://dx.doi.org/10.18632/oncotarget.20262] [PMID: 29190887]
[132]
Dong L, Li G, Li Y, Zhu Z. Upregulation of long noncoding RNA GAS5 inhibits lung cancer cell proliferation and metastasis via miR-205/PTEN axis. Med Sci Monit 2019; 25: 2311-9.
[http://dx.doi.org/10.12659/MSM.912581] [PMID: 30926767]
[133]
Jiang M, Zhang P, Hu G, et al. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem 2013; 383(1-2): 67-75.
[http://dx.doi.org/10.1007/s11010-013-1755-y] [PMID: 23881177]
[134]
Xu L-B, Xiong J, Zhang Y-H, et al. miR-205-3p promotes lung cancer progression by targeting APBB2. Mol Med Rep 2021; 24(2): 1-11.
[http://dx.doi.org/10.3892/mmr.2021.12227]
[135]
Zhao YL, Zhang JX, Yang JJ, et al. MiR-205-5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer. Thorac Cancer 2022; 13(6): 832-43.
[http://dx.doi.org/10.1111/1759-7714.14331] [PMID: 35076182]
[136]
Sromek M, Glogowski M, Chechlinska M, et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol 2017; 40(5): 529-36.
[http://dx.doi.org/10.1007/s13402-017-0334-8] [PMID: 28634901]
[137]
Zheng DH, Wang X, Lu LN, et al. MiR-638 serves as a tumor suppressor by targeting HOXA9 in glioma. Eur Rev Med Pharmacol Sci 2018; 22(22): 7798-806.
[PMID: 30536324]
[138]
Li D, Wang Q, Liu C, et al. Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation. Toxicol Sci 2012; 125(2): 382-91.
[http://dx.doi.org/10.1093/toxsci/kfr299] [PMID: 22048643]
[139]
Wang F, Lou JF, Cao Y, et al. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy. Exp Mol Med 2015; 47(5): e162-2.
[http://dx.doi.org/10.1038/emm.2015.17] [PMID: 25952770]
[140]
Xia Y, Wu Y, Liu B, Wang P, Chen Y. Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. FEBS Lett 2014; 588(14): 2238-45.
[http://dx.doi.org/10.1016/j.febslet.2014.05.002] [PMID: 24842609]
[141]
Fang K, Chen X, Qiu F, Xu J, Xiong H, Zhang Z. Serum-Derived exosomes-mediated circular rna arhgap10 modulates the progression of non-small-cell lung cancer through the miR-638/FAM83F axis. Cancer Biother Radiopharm 2022; 37(2): 96-110.
[PMID: 32783691]
[142]
Ma K, Pan X, Fan P, et al. Loss of miR-638 in vitro promotes cell invasion and a mesenchymal-like transition by influencing SOX2 expression in colorectal carcinoma cells. Mol Cancer 2014; 13(1): 118.
[http://dx.doi.org/10.1186/1476-4598-13-118] [PMID: 24885288]
[143]
Wu X, Bhayani MK, Dodge CT, et al. Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget 2013; 4(9): 1388-98.
[http://dx.doi.org/10.18632/oncotarget.1239] [PMID: 23963114]
[144]
Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: Diagnostic implications of serum miR-1233 levels. PLoS One 2011; 6(9): e25787.
[http://dx.doi.org/10.1371/journal.pone.0025787] [PMID: 21984948]
[145]
Jin JJ, Liu YH, Si JM, Ni R, Wang J. Overexpression of miR-1290 contributes to cell proliferation and invasion of non small cell lung cancer by targeting interferon regulatory factor 2. Int J Biochem Cell Biol 2018; 95: 113-20.
[http://dx.doi.org/10.1016/j.biocel.2017.12.017] [PMID: 29275213]
[146]
Xiao X, Yang D, Gong X, Mo D, Pan S, Xu J. miR-1290 promotes lung adenocarcinoma cell proliferation and invasion by targeting SOCS4. Oncotarget 2018; 9(15): 11977-88.
[http://dx.doi.org/10.18632/oncotarget.24046] [PMID: 29552286]
[147]
Zhang WC, Chin TM, Yang H, et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun 2016; 7(1): 11702.
[http://dx.doi.org/10.1038/ncomms11702] [PMID: 27325363]
[148]
Mo D, Gu B, Gong X, et al. miR-1290 is a potential prognostic biomarker in non-small cell lung cancer. J Thorac Dis 2015; 7(9): 1570-9.
[PMID: 26543604]
[149]
Wu Y, Wei J, Zhang W, Xie M, Wang X, Xu J. Serum exosomal miR-1290 is a potential biomarker for lung adenocarcinoma. OncoTargets Ther 2020; 13: 7809-18.
[http://dx.doi.org/10.2147/OTT.S263934] [PMID: 32801784]
[150]
Kim G, An HJ, Lee MJ, et al. Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer 2016; 91: 15-22.
[http://dx.doi.org/10.1016/j.lungcan.2015.11.013] [PMID: 26711929]
[151]
Zhang H, Guo J, Mao L, et al. Up-regulation of miR-24-1-5p is involved in the chemoprevention of colorectal cancer by black raspberry anthocyanins. Br J Nutr 2019; 122(5): 518-26.
[http://dx.doi.org/10.1017/S0007114518003136] [PMID: 30375302]
[152]
Wang S, Zhang R, Claret FX, Yang H. Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. Mol Cancer Ther 2014; 13(12): 3163-74.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0317] [PMID: 25319395]
[153]
Wang XH, Gan CZ, Xie JY. Inhibition of miR-24 suppresses malignancy of human non-small cell lung cancer cells by targeting WWOX in vitro and in vivo. Thorac Cancer 2018; 9(12): 1583-93.
[http://dx.doi.org/10.1111/1759-7714.12824] [PMID: 30307120]
[154]
Liu Z, Jiang L, Zhang G, Li S, Jiang X. MiR-24 promotes migration and invasion of non-small cell lung cancer by targeting ZNF367. J BUON 2018; 23(5): 1413-9.
[155]
Zhao G, Liu L, Zhao T, et al. Upregulation of miR-24 promotes cell proliferation by targeting NAIF1 in non-small cell lung cancer. Tumour Biol 2015; 36(5): 3693-701.
[http://dx.doi.org/10.1007/s13277-014-3008-4] [PMID: 25725584]
[156]
Du WW, Fang L, Li M, et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J Cell Sci 2013; 126(Pt 6): 1440-53.
[http://dx.doi.org/10.1242/jcs.118299] [PMID: 23418360]
[157]
Akbarzadeh Khiavi M, Safary A, Barar J, Ajoolabady A, Somi MH, Omidi Y. Multifunctional nanomedicines for targeting epidermal growth factor receptor in colorectal cancer. Cell Mol Life Sci 2020; 77(6): 997-1019.
[PMID: 31563999]
[158]
Xie L, Wang T, Yu S, et al. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clin Biochem 2011; 44(2-3): 216-20.
[http://dx.doi.org/10.1016/j.clinbiochem.2010.11.002] [PMID: 21093424]
[159]
Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 2014; 229(1): 97-9.
[PMID: 23794259]
[160]
Chen W, Fu W, Deng Q, et al. Multiple metals exposure and chromosome damage: Exploring the mediation effects of microRNAs and their potentials in lung carcinogenesis. Environ Int 2019; 122: 291-300.
[http://dx.doi.org/10.1016/j.envint.2018.11.020] [PMID: 30455104]
[161]
Yan L, Ma J, Zhu Y, et al. miR-24-3p promotes cell migration and proliferation in lung cancer by targeting SOX7. J Cell Biochem 2018; 119(5): 3989-98.
[http://dx.doi.org/10.1002/jcb.26553] [PMID: 29231262]
[162]
Zhou Q, Long L, Zhou T, Tian J, Zhou B. Demethylation of MicroRNA-124a genes attenuated proliferation of rheumatoid arthritis derived fibroblast-like synoviocytes and synthesis of tumor necrosis factor-α. PLoS One 2016; 11(11): e0164207.
[http://dx.doi.org/10.1371/journal.pone.0164207] [PMID: 27824863]
[163]
Luo P, Yang Q, Cong LL, et al. Identification of miR-124a as a novel diagnostic and prognostic biomarker in non-small cell lung cancer for chemotherapy. Mol Med Rep 2017; 16(1): 238-46.
[http://dx.doi.org/10.3892/mmr.2017.6595] [PMID: 28534972]
[164]
Sun Y, Ai X, Shen S, Lu S. NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget 2015; 6(10): 8244-54.
[http://dx.doi.org/10.18632/oncotarget.3135] [PMID: 25749519]
[165]
Yang Q, Wan L, Xiao C, et al. Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer. Oncol Lett 2017; 14(3): 3429-36.
[http://dx.doi.org/10.3892/ol.2017.6607] [PMID: 28927097]
[166]
Zarredar H, Pashapour S, Farajnia S, et al. Targeting the KRAS, p38α and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor. J Cell Biochem 2019; 120(6): 10670-7.
[http://dx.doi.org/10.1002/jcb.28357] [PMID: 30656741]
[167]
Li S, Mei Z, Hu HB, Zhang X. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol 2018; 233(9): 6679-88.
[http://dx.doi.org/10.1002/jcp.26325] [PMID: 29215698]
[168]
Aftabi Y, Ansarin K, Shanehbandi D, et al. Long non-coding RNAs as potential biomarkers in the prognosis and diagnosis of lung cancer: A review and target analysis. IUBMB Life 2021; 73(2): 307-27.
[http://dx.doi.org/10.1002/iub.2430] [PMID: 33369006]
[169]
Wang M, Meng B, Liu Y, Yu J, Chen Q, Liu Y. MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3. Cell Physiol Biochem 2017; 44(5): 2017-28.
[http://dx.doi.org/10.1159/000485907] [PMID: 29237164]
[170]
Hu FY, Cao XN, Xu QZ, et al. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. J Huazhong University of Science and Technology 2016; 36(6): 839-45.
[http://dx.doi.org/10.1007/s11596-016-1672-x] [PMID: 27924500]
[171]
Liu T, Zhu J, Du W, et al. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma. Respir Res 2020; 21(1): 227.
[http://dx.doi.org/10.1186/s12931-020-01491-0] [PMID: 32873299]
[172]
Qi MM, Ge F, Chen XJ, Tang C, Ma J. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3. Eur Rev Med Pharmacol Sci 2019; 23(12): 5242-50.
[PMID: 31298375]
[173]
Yu W, Peng W, Jiang H, Sha H, Li J. LncRNA HOXA11-AS promotes proliferation and invasion by targeting miR-124 in human non-small cell lung cancer cells. Tumour Biol 2017; 39(10): 1010428317721440.
[http://dx.doi.org/10.1177/1010428317721440] [PMID: 29034803]
[174]
Tan X, Zhang C, Gao W, Sun B, Jiang B, Song P. Overexpression of microRNA-124-5p sensitizes non-small cell lung cancer cells to treatment with 5-fluorouracil via AEG-1 regulation. Oncol Lett 2021; 21(1): 5.
[PMID: 33240411]
[175]
Xiao H. MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2. Cell Mol Biol Lett 2019; 24(1): 60.
[http://dx.doi.org/10.1186/s11658-019-0188-3] [PMID: 31832068]
[176]
Vera O, Jimenez J, Pernia O, et al. DNA Methylation of miR-7 is a mechanism involved in platinum response through MAFG overexpression in cancer cells. Theranostics 2017; 7(17): 4118-34.
[http://dx.doi.org/10.7150/thno.20112] [PMID: 29158814]
[177]
Liu H, Wu X, Huang J, Peng J, Guo L. miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1. Int J Exp Pathol 2015; 96(4): 240-7.
[http://dx.doi.org/10.1111/iep.12131] [PMID: 26108539]
[178]
Rodríguez-Antolín C, Felguera-Selas L, Pernía O, et al. miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients. Cell Biosci 2019; 9(1): 63-3.
[http://dx.doi.org/10.1186/s13578-019-0326-7] [PMID: 31406565]
[179]
Lai J, Yang H, Zhu Y, Ruan M, Huang Y, Zhang Q. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer. BMC Cancer 2019; 19(1): 602.
[http://dx.doi.org/10.1186/s12885-019-5798-7] [PMID: 31215481]
[180]
Li J, Zheng Y, Sun G, Xiong S. Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling. Oncol Rep 2014; 32(6): 2511-6.
[http://dx.doi.org/10.3892/or.2014.3519] [PMID: 25334070]
[181]
Zhang X, Yang D, Wei Y. Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer. OncoTargets Ther 2018; 11: 3979-87.
[http://dx.doi.org/10.2147/OTT.S158316] [PMID: 30022841]
[182]
Su C, Han Y, Zhang H, et al. CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-κB signalling. J Cell Mol Med 2018; 22(6): 3097-107.
[http://dx.doi.org/10.1111/jcmm.13587] [PMID: 29532994]
[183]
He X, Li C, Wu X, Yang G. Docetaxel inhibits the proliferation of non-small-cell lung cancer cells via upregulation of microRNA-7 expression. Int J Clin Exp Pathol 2015; 8(8): 9072-80.
[PMID: 26464649]
[184]
Wang Y, Dakhlallah D, Moldovan L, et al. Circulating MicroRNAs as Biomarkers: MicroRNA in Regenerative Medicine. Elsevier 2015; 1093-125.
[185]
Lu J-W, Hsia Y, Yang W-Y, et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 2012; 33(1): 209-19.
[http://dx.doi.org/10.1093/carcin/bgr224] [PMID: 22021908]
[186]
Wu X, Li S, Xu X, et al. The potential value of miR-1 and miR-374b as biomarkers for colorectal cancer. Int J Clin Exp Pathol 2015; 8(3): 2840-51.
[PMID: 26045793]
[187]
Wang Y, Luo X, Liu Y, Han G, Sun D. Long noncoding RNA RMRP promotes proliferation and invasion via targeting miR-1-3p in non-small-cell lung cancer. J Cell Biochem 2019; 120(9): 15170-81.
[http://dx.doi.org/10.1002/jcb.28779] [PMID: 31050363]
[188]
Zhao Q, Zhang B, Shao Y, et al. Correlation between the expression levels of miR-1 and PIK3CA in non-small-cell lung cancer and their relationship with clinical characteristics and prognosis. Future Oncol 2014; 10(1): 49-57.
[http://dx.doi.org/10.2217/fon.13.242] [PMID: 24328409]
[189]
Yu QQ, Wu H, Huang X, et al. MiR-1 targets PIK3CA and inhibits tumorigenic properties of A549 cells. Biomed Pharmacother 2014; 68(2): 155-61.
[190]
Chiu KL, Lin YS, Kuo TT, et al. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget 2017; 8(29): 47365-78.
[http://dx.doi.org/10.18632/oncotarget.17648] [PMID: 28537886]
[191]
Jiao D, Chen J, Li Y, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med 2018; 22(7): 3526-36.
[http://dx.doi.org/10.1111/jcmm.13629] [PMID: 29664235]
[192]
Jiang S, Zhang H-W, Lu M-H, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010; 70(8): 3119-27.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-4250] [PMID: 20354188]
[193]
Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 2007; 67(22): 10782-8.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1484] [PMID: 18006822]
[194]
Gironella M, Seux M, Xie M-J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104(41): 16170-5.
[http://dx.doi.org/10.1073/pnas.0703942104] [PMID: 17911264]
[195]
Donnem T, Eklo K, Berg T, et al. Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med 2011; 9(1): 6.
[http://dx.doi.org/10.1186/1479-5876-9-6] [PMID: 21219656]
[196]
Wang Y, Li J, Tong L, et al. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: A meta-analysis. Jpn J Clin Oncol 2013; 43(8): 813-20.
[http://dx.doi.org/10.1093/jjco/hyt084] [PMID: 23817461]
[197]
Xue X, Liu Y, Wang Y, et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 2016; 7(51): 84508-19.
[http://dx.doi.org/10.18632/oncotarget.13022] [PMID: 27811366]
[198]
Xu T-P, Zhu C-H, Zhang J, et al. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev 2013; 14(12): 7085-90.
[http://dx.doi.org/10.7314/APJCP.2013.14.12.7085] [PMID: 24460255]
[199]
Wang N, Guo H, Dong Z, et al. Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer. Cancer Manag Res 2018; 10: 3463-71.
[http://dx.doi.org/10.2147/CMAR.S170481] [PMID: 30254489]
[200]
Yang M, Shen H, Qiu C, et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2013; 49(3): 604-15.
[http://dx.doi.org/10.1016/j.ejca.2012.09.031] [PMID: 23099007]
[201]
Gao Y, Fu S, Jiang W, Li B, Tian Y, Fu X. Association of MiR-155 expression with prognosis in resected stage III non-small cell lung cancer. Chinese J Lung Cancer 2014; 17(5): 417-23.
[202]
Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: Discovery, function and future perspectives. Cell Death Differ 2010; 17(2): 215-20.
[http://dx.doi.org/10.1038/cdd.2009.69] [PMID: 19498445]
[203]
Chen F, Hou SK, Fan HJ, Liu YF. MiR-15a-16 represses Cripto and inhibits NSCLC cell progression. Mol Cell Biochem 2014; 391(1-2): 11-9.
[http://dx.doi.org/10.1007/s11010-014-1981-y] [PMID: 24500260]
[204]
Yang T, Thakur A, Chen T, et al. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol 2015; 36(6): 4357-65.
[http://dx.doi.org/10.1007/s13277-015-3075-1] [PMID: 25874488]
[205]
Bozok Çetintaş V, Tetik Vardarlı A, Düzgün Z, et al. miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells. Tumour Biol 2016; 37(2): 1739-51.
[http://dx.doi.org/10.1007/s13277-015-3950-9] [PMID: 26314859]
[206]
Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69(13): 5553-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4277] [PMID: 19549910]
[207]
He J. Knocking down MiR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro. Saudi J Biol Sci 2017; 24(8): 1859-65.
[http://dx.doi.org/10.1016/j.sjbs.2017.11.028] [PMID: 29551936]
[208]
Ergun S, Güney S, Temiz E, Petrovic N, Gunes S. Significance of miR-15a-5p and CNKSR3 as novel prognostic biomarkers in non-small cell lung cancer. Anticancer Agents Med Chem 2018; 18(12): 1695-701.
[http://dx.doi.org/10.2174/1871520618666180718100656] [PMID: 30019650]
[209]
Yang FR, Li HJ, Li TT, Zhao YF, Liu ZK, Li XR. Prognostic value of MicroRNA-15a in human cancers: A meta-analysis and bioinformatics. BioMed Res Int 2019; 2019: 2063823.
[http://dx.doi.org/10.1155/2019/2063823] [PMID: 31061821]
[210]
Li J, Li M, Gao F, Ge X. Serum microRNA-15a level acts as a potential diagnostic and prognostic biomarker for human esophageal squamous cell carcinoma. Cancer Biomark 2017; 18(1): 11-7.
[http://dx.doi.org/10.3233/CBM-160667] [PMID: 27802201]

Rights & Permissions Print Cite
Article Metrics
54
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy